Role of ghrelin in the regulation of vasopressin release in conscious rats

GH secretagogue (GHS) is a small, synthetic compound that has the potential to stimulate GH release via its specific receptors (GHS-R). Ghrelin is a novel 28-amino acid peptide recently isolated from human and rat stomach, and it is thought to be the endogenous ligand for GHS-R. Ghrelin has a variet...

Full description

Saved in:
Bibliographic Details
Published inEndocrinology (Philadelphia) Vol. 143; no. 5; pp. 1589 - 1593
Main Authors Ishizaki, Seiji, Murase, Takashi, Sugimura, Yoshihisa, Kakiya, Satoshi, Yokoi, Hisashi, Tachikawa, Kazushige, Arima, Hiroshi, Miura, Yoshitaka, Oiso, Yutaka
Format Journal Article
LanguageEnglish
Published United States 01.05.2002
Subjects
Animals
Antibodies, Blocking - pharmacology
Blood Pressure - drug effects
Blood Proteins - metabolism
Dose-Response Relationship, Drug
Ghrelin
Injections, Intravenous
Injections, Intraventricular
Kinetics
Male
Neurons - drug effects
Neurons - physiology
Neuropeptide Y - antagonists & inhibitors
Neuropeptide Y - physiology
Peptide Hormones
Peptides - administration & dosage
Peptides - pharmacology
Rats
Rats, Sprague-Dawley
Sodium - blood
Vasopressins - blood
Vasopressins - metabolism
Online AccessGet full text

Cover

More Information
Summary:GH secretagogue (GHS) is a small, synthetic compound that has the potential to stimulate GH release via its specific receptors (GHS-R). Ghrelin is a novel 28-amino acid peptide recently isolated from human and rat stomach, and it is thought to be the endogenous ligand for GHS-R. Ghrelin has a variety of physiological functions such as the stimulation of GH release or the increase of food intake by activating NPY neurons. In the present study, we investigated the effects of ghrelin on AVP release in conscious rats. Intracerebroventricular (icv) administration of ghrelin increased the plasma AVP concentration in a dose-dependent manner (1-1000 pmol/rat), and its effect was observed as late as 60 min after the administration. Icv injection of ghrelin caused no significant change in plasma osmolality, plasma volume, or arterial blood pressure. Iv administration of ghrelin (10 nmol/rat) also increased the plasma AVP concentration, which was accompanied by a significant decrease in arterial blood pressure. Pretreatment with antiserum against NPY significantly reduced the plasma AVP increase induced by icv administration of ghrelin. These results suggest that ghrelin plays a stimulatory role in AVP release, which is possibly mediated by NPY neurons.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0013-7227
DOI:10.1210/en.143.5.1589